BR112022003562A2 - Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos - Google Patents
Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãosInfo
- Publication number
- BR112022003562A2 BR112022003562A2 BR112022003562A BR112022003562A BR112022003562A2 BR 112022003562 A2 BR112022003562 A2 BR 112022003562A2 BR 112022003562 A BR112022003562 A BR 112022003562A BR 112022003562 A BR112022003562 A BR 112022003562A BR 112022003562 A2 BR112022003562 A2 BR 112022003562A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- diyl
- prophylaxis
- treatment
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 210000000056 organ Anatomy 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- -1 4,5-dihydroisoxazol-3,5-diyl Chemical group 0.000 abstract 7
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
Abstract
composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos. a presente invenção refere-se a compostos de fórmula (i), em que que ar1, a, r1 e r2 são como descritos na descrição, e a é 4,5-di-hidroisoxazol-3,5-di-ila, imidaolidin-4-ona-1,3-di-ila, oxazol-2-ona-3,5-di-ila e oxazolidina-2-ona-3,5-di-ila, 1,2,3-triazol-1,4-di-ila, isoxazol-3,5-di-ila, imidazol-1,4-di-ila e isotiazol-3,5-di-ila; e a sua preparação, a sais farmaceuticamente aceitáveis dos mesmos e ao uso dos mesmos como agentes farmacêuticos, a composições farmacêuticas contendo um ou mais compostos de fórmula (i) e, especialmente, ao seu uso como inibidores de galectina-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019073063 | 2019-08-29 | ||
| PCT/EP2020/074121 WO2021038068A1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003562A2 true BR112022003562A2 (pt) | 2022-05-24 |
Family
ID=72561746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003562A BR112022003562A2 (pt) | 2019-08-29 | 2020-08-28 | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220281855A1 (pt) |
| EP (1) | EP4021904B1 (pt) |
| JP (1) | JP2022546029A (pt) |
| KR (1) | KR20220053622A (pt) |
| CN (1) | CN114585619B (pt) |
| AU (1) | AU2020338816A1 (pt) |
| BR (1) | BR112022003562A2 (pt) |
| CA (1) | CA3148365A1 (pt) |
| ES (1) | ES2972551T3 (pt) |
| HR (1) | HRP20240297T1 (pt) |
| HU (1) | HUE066221T2 (pt) |
| IL (1) | IL290815A (pt) |
| MA (1) | MA57000B1 (pt) |
| MX (1) | MX2022002339A (pt) |
| PL (1) | PL4021904T3 (pt) |
| RS (1) | RS65294B1 (pt) |
| SA (1) | SA522431777B1 (pt) |
| TW (1) | TW202122092A (pt) |
| WO (1) | WO2021038068A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116348463A (zh) | 2020-10-06 | 2023-06-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷的螺衍生物 |
| MX2023010241A (es) | 2021-03-03 | 2023-09-12 | Idorsia Pharmaceuticals Ltd | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| JP6055928B2 (ja) | 2012-10-10 | 2016-12-27 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物 |
| IN2015DN02573A (pt) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| US10774102B2 (en) | 2015-01-30 | 2020-09-15 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| KR20240008398A (ko) | 2015-07-06 | 2024-01-18 | 길리애드 사이언시즈, 인코포레이티드 | Cot 조정제 및 그의 사용 방법 |
| EP3621975A1 (en) | 2017-05-12 | 2020-03-18 | Galectin Sciences, LLC | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11267811B2 (en) * | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP2021501180A (ja) | 2017-10-31 | 2021-01-14 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用 |
| WO2020078807A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Prodrug of galactoside inhibitors of galectins |
| CA3113956A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| US11447517B2 (en) | 2018-11-21 | 2022-09-20 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
-
2020
- 2020-08-28 HR HRP20240297TT patent/HRP20240297T1/hr unknown
- 2020-08-28 BR BR112022003562A patent/BR112022003562A2/pt unknown
- 2020-08-28 CN CN202080060134.6A patent/CN114585619B/zh active Active
- 2020-08-28 EP EP20775188.4A patent/EP4021904B1/en active Active
- 2020-08-28 PL PL20775188.4T patent/PL4021904T3/pl unknown
- 2020-08-28 ES ES20775188T patent/ES2972551T3/es active Active
- 2020-08-28 TW TW109129635A patent/TW202122092A/zh unknown
- 2020-08-28 WO PCT/EP2020/074121 patent/WO2021038068A1/en active Application Filing
- 2020-08-28 RS RS20240319A patent/RS65294B1/sr unknown
- 2020-08-28 US US17/638,799 patent/US20220281855A1/en active Pending
- 2020-08-28 MX MX2022002339A patent/MX2022002339A/es unknown
- 2020-08-28 CA CA3148365A patent/CA3148365A1/en active Pending
- 2020-08-28 MA MA57000A patent/MA57000B1/fr unknown
- 2020-08-28 AU AU2020338816A patent/AU2020338816A1/en active Pending
- 2020-08-28 JP JP2022512854A patent/JP2022546029A/ja active Pending
- 2020-08-28 HU HUE20775188A patent/HUE066221T2/hu unknown
- 2020-08-28 KR KR1020227009790A patent/KR20220053622A/ko unknown
-
2022
- 2022-02-22 IL IL290815A patent/IL290815A/en unknown
- 2022-02-27 SA SA522431777A patent/SA522431777B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021038068A1 (en) | 2021-03-04 |
| SA522431777B1 (ar) | 2024-04-30 |
| CA3148365A1 (en) | 2021-03-04 |
| EP4021904B1 (en) | 2024-01-03 |
| ES2972551T3 (es) | 2024-06-13 |
| CN114585619B (zh) | 2024-09-27 |
| HUE066221T2 (hu) | 2024-07-28 |
| RS65294B1 (sr) | 2024-04-30 |
| MX2022002339A (es) | 2022-04-06 |
| US20220281855A1 (en) | 2022-09-08 |
| EP4021904C0 (en) | 2024-01-03 |
| PL4021904T3 (pl) | 2024-05-13 |
| CN114585619A (zh) | 2022-06-03 |
| JP2022546029A (ja) | 2022-11-02 |
| KR20220053622A (ko) | 2022-04-29 |
| HRP20240297T1 (hr) | 2024-05-10 |
| IL290815A (en) | 2022-04-01 |
| MA57000B1 (fr) | 2024-03-29 |
| EP4021904A1 (en) | 2022-07-06 |
| TW202122092A (zh) | 2021-06-16 |
| AU2020338816A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| BR0308495A (pt) | Composto, formulação farmacêutica, métodos para ativar receptores de 5-ht1f, para inibir o extravasamento de proteìna neuronal, para tratar ou prevenir enxaqueca em um mamìfero e para preparar um composto, uso de um composto, e, processo para preparar um composto | |
| BR0015203A (pt) | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente | |
| BR0213522A (pt) | Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids | |
| BR112022003562A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de fibrose de órgãos | |
| ES2185307T3 (es) | Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion. | |
| BR0210874A (pt) | Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR0312000A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos | |
| BR112023003832A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
| BR112023000560A2 (pt) | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| KR940703655A (ko) | 약제학적 조성물과 그 제조방법 | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR112022018173A2 (pt) | Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo | |
| BRPI0811478B8 (pt) | compostos de morfinano, composição contendo os ditos compostos, usos dos mesmos, embalagem e formas de dosagem separadas | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR112022021735A2 (pt) | Compostos úteis para inibir cinase ret | |
| BR112023002031A2 (pt) | Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos | |
| BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |